

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549**

**Final Stakeholder List**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Arcellx and Kite, Gilead Sciences (anitocabtagene autoleucel)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• African Caribbean Leukaemia Trust</li> <li>• Anthony Nolan</li> <li>• Black Health Agency for Equality</li> <li>• Blood Cancer UK</li> <li>• Cancer Black Care</li> <li>• Cancer52</li> <li>• DKMS</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Kevin Kararwa Leukaemia Trust</li> <li>• Leukaemia Cancer Society</li> <li>• Leukaemia Care</li> <li>• Leukaemia UK</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Myeloma UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Geriatrics Society</li> <li>• British Oncology Pharmacy Association</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> <li>• British Society of Blood and Marrow Transplant and Cellular Therapy</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Cell and Gene Therapy Catapult</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AmaroX (lenalidomide, pomalidomide)</li> <li>• Amgen (carfilzomib)</li> <li>• Aspire Pharma (bortezomib)</li> <li>• Aurobindo Pharma – Milpharm (bortezomib)</li> <li>• Biocon Pharma (lenalidomide)</li> <li>• Biotech Pharma (bortezomib)</li> <li>• Dr. Reddy's Laboratories UK (bortezomib)</li> <li>• GlaxoSmithKline UK (belantamab mafodotin)</li> <li>• Grindeks Kalceks UK (lenalidomide, pomalidomide)</li> </ul>

Final stakeholder list for the evaluation of anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549

Issue date: June 2026

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Myeloma Forum</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Blood and Marrow Transplant Clinical Reference Group</li> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Janssen-Cilag, a Johnson &amp; Johnson Company (bortezomib, daratumumab, talquetamab, teclistamab)</li> <li>• Menarini Stemline UK (selinexor)</li> <li>• MSN Laboratories Europe (bortezomib)</li> <li>• Pfizer (elranatamab)</li> <li>• pharmaand GmbH (panobinostat)</li> <li>• Regeneron Pharmaceuticals (linvoseltamab)</li> <li>• Sandoz (bortezomib)</li> <li>• Sanofi (isatuximab)</li> <li>• Sun Pharmaceutical Company (bortezomib, lenalidomide)</li> <li>• Takeda UK (ixazomib)</li> <li>• Teva UK (lenalidomide)</li> <li>• Thornton &amp; Ross (bortezomib, lenalidomide, pomalidomide)</li> <li>• Viartis, formerly Mylan or Upjohn (lenalidomide, pomalidomide)</li> <li>• Wockhardt UK (pomalidomide)</li> <li>• Zentiva (pomalidomide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Haematology</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• Leukaemia Busters</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Final stakeholder list for the evaluation of anitocabtagene autoleucl for treating relapsed or refractory multiple myeloma ID6549

Issue date: June 2026

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.